JP2019502719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502719A5 JP2019502719A5 JP2018536488A JP2018536488A JP2019502719A5 JP 2019502719 A5 JP2019502719 A5 JP 2019502719A5 JP 2018536488 A JP2018536488 A JP 2018536488A JP 2018536488 A JP2018536488 A JP 2018536488A JP 2019502719 A5 JP2019502719 A5 JP 2019502719A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nociception
- corneal nociception
- patient
- corneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000020341 sensory perception of pain Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000000699 topical Effects 0.000 claims 3
- 108010003541 Platelet Activating Factor Proteins 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 206010052143 Ocular discomfort Diseases 0.000 claims 1
- 206010068760 Ulcers Diseases 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Claims (8)
- 患者における角膜の侵害受容を処置する方法であって、前記方法は、前記患者の少なくとも1つの眼に、約0.01%(w/v)〜約10%(w/v)の濃度を有する局所眼科用製剤中の治療上有効な量の以下の化合物、
方法。 - 前記化合物は、局所眼科用製剤中で前記患者の1つあるいは両方の眼に1日1回投与される、請求書1に記載の方法。
- 前記局所眼科用製剤は、溶液、エマルジョン、分散体、懸濁液、軟膏、およびゲルから成る群から選択される1つである、請求項2に記載の方法。
- 前記方法は角膜の侵害受容の著しい減少を結果としてもたらす、請求項1に記載の方法。
- 前記角膜の侵害受容は眼表面に関連する、請求項4に記載の方法。
- 前記角膜の侵害受容は環境的にあるいは疾患により誘発されるドライアイ、眼表面の傷害、潰瘍、環境汚染、および眼科手術から成る群から選択される1つにより生成される、請求項1に記載の方法。
- 前記化合物は、血小板活性化因子(PAF)受容体と相互作用する、請求項1に記載の方法。
- 前記角膜の侵害受容は、眼の不快感および眼痛からなる群から選択される1つである、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/006,085 US9827225B2 (en) | 2016-01-25 | 2016-01-25 | Use of prostacyclin antagonists for treating ocular surface nociception |
US15/006,085 | 2016-01-25 | ||
PCT/US2017/014677 WO2017132115A1 (en) | 2016-01-25 | 2017-01-24 | Use of prostacyclin antagonists for treating ocular surface nociception |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019502719A JP2019502719A (ja) | 2019-01-31 |
JP2019502719A5 true JP2019502719A5 (ja) | 2020-02-27 |
JP6752439B2 JP6752439B2 (ja) | 2020-09-09 |
Family
ID=59360031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018536488A Active JP6752439B2 (ja) | 2016-01-25 | 2017-01-24 | 眼表面の侵害受容を処置するためのプロスタサイクリンアンタゴニストの使用 |
Country Status (10)
Country | Link |
---|---|
US (4) | US9827225B2 (ja) |
EP (1) | EP3407975B1 (ja) |
JP (1) | JP6752439B2 (ja) |
KR (1) | KR20180104108A (ja) |
CN (1) | CN108883307B (ja) |
AU (1) | AU2017212343B2 (ja) |
CA (1) | CA3012197A1 (ja) |
ES (1) | ES2894916T3 (ja) |
MX (1) | MX2018009125A (ja) |
WO (1) | WO2017132115A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
WO2022170112A1 (en) * | 2021-02-05 | 2022-08-11 | Jenivision Inc. | Compositions and methods for periorbital administration of ep2 receptor agonists |
CA3212050A1 (en) * | 2021-03-18 | 2022-09-22 | Weizhen Wang | Methods and compositions for treating eye diseases |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU674038B2 (en) * | 1992-10-13 | 1996-12-05 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
NZ331480A (en) | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
US6184242B1 (en) | 1997-09-04 | 2001-02-06 | Syntex Usa (Llc) | 2-(substituted-phenyl)amino-imidazoline derivatives |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
ATE305002T1 (de) * | 2000-11-14 | 2005-10-15 | Hoffmann La Roche | Substituierte 2-phenylaminoimidazolin-phenyl- ketonderivate als ip-antagonisten |
BRPI0409957A (pt) * | 2003-05-01 | 2006-04-25 | Hoffmann La Roche | imidazolin-2-ilaminofenil amidas |
US9610990B2 (en) * | 2009-05-08 | 2017-04-04 | Titan Trailers Inc. | Apparatus and method for warming the floor of a trailer |
WO2013096501A1 (en) * | 2011-12-21 | 2013-06-27 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
WO2014143592A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid ip receptors |
US9820954B2 (en) | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
US9827225B2 (en) | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
-
2016
- 2016-01-25 US US15/006,085 patent/US9827225B2/en active Active
-
2017
- 2017-01-24 ES ES17744748T patent/ES2894916T3/es active Active
- 2017-01-24 AU AU2017212343A patent/AU2017212343B2/en active Active
- 2017-01-24 MX MX2018009125A patent/MX2018009125A/es unknown
- 2017-01-24 JP JP2018536488A patent/JP6752439B2/ja active Active
- 2017-01-24 CN CN201780014505.5A patent/CN108883307B/zh active Active
- 2017-01-24 CA CA3012197A patent/CA3012197A1/en active Pending
- 2017-01-24 WO PCT/US2017/014677 patent/WO2017132115A1/en active Application Filing
- 2017-01-24 EP EP17744748.9A patent/EP3407975B1/en active Active
- 2017-01-24 KR KR1020187024480A patent/KR20180104108A/ko active Search and Examination
- 2017-09-20 US US15/710,438 patent/US20180008578A1/en not_active Abandoned
-
2019
- 2019-09-05 US US16/562,063 patent/US20200345697A1/en not_active Abandoned
-
2021
- 2021-03-23 US US17/210,213 patent/US11857537B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019534867A5 (ja) | ||
CA2784492C (en) | Non-irritating ophthalmic povidone-iodine compositions | |
POST et al. | Demodex folliculorum and blepharitis | |
JP2019536784A5 (ja) | ||
JP2018529693A5 (ja) | ||
JP2019532931A (ja) | 眼瞼炎の治療に使用するための医薬組成物 | |
EA201000441A1 (ru) | Водные офтальмологические препараты | |
JP2019502719A5 (ja) | ||
RU2018114926A (ru) | Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения | |
JP2011516477A5 (ja) | ||
JP6014033B2 (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
JP2017520527A5 (ja) | ||
CH711969A2 (it) | Composizione per il trattamento della presbiopia. | |
JP2020531511A5 (ja) | ||
EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
JP2009500398A5 (ja) | ||
WO2010075315A2 (en) | Topical formulations of flap inhibitors for administration to an eye | |
JP2018528169A5 (ja) | ||
JP2017533228A5 (ja) | ||
RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
JP2017527600A5 (ja) | ||
JP2009500397A5 (ja) | ||
RU2314102C1 (ru) | Способ комплексного лечения дисфункции мейбомиевых желез | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. |